Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

SGLT2 inhibitors were developed to block the co-transport of sodium and glucose in the renal tubule to increase renal glucose excretion as a treatment for diabetes. In adults, SGLT2 inhibitors improve ...

The drug is naturally eliminated from the body, so it is unlikely to accumulate or create new problems for people with kidney disease who are exposed to very small doses of this medication.

Physicians are urged to remain vigilant, monitoring for signs of pancreatitis and closely tracking kidney function in patients using these medications. Kidney issues, in particular, can develop ...

While these adverse effects are uncommon, they can be very serious; physicians must be vigilant for signs of pancreatitis and monitor kidney function among people taking GLP-1RA medications.

Background: Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease worldwide. Epidemiological evidence of the association between urinary sodium excretion and ... individuals ...